Drug Profile
Mipasetamab uzoptirine - ADC Therapeutics
Alternative Names: 1H12-GaINAcN3; 1H12-HAKB; ADCT-601; BGB 601; Mipasetamab - ADC TherapeuticsLatest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator ADC Therapeutics
- Developer ADC Therapeutics; Overland ADCT BioPharma
- Class Antibodies; Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Pyrroles
- Mechanism of Action DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 13 Mar 2024 Efficacy and adverse events data from a phase Ib trial in Solid tumours released by ADC Therapeutics
- 26 Jun 2023 Preclinical trials in Solid tumours in China (IV) (Overland ADCT Biopharma pipeline, June 2023)
- 31 Oct 2022 ADC Therapeutics and OxSonics Therapeutics enters into a collaboration agreement to assess the ability of SonoTran® to enhance the efficacy of ADCT 601